All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-03-27T08:42:27.000Z

EBMT 2018 | Retrospective analysis of the role of allo-SCT in PTCL

Mar 27, 2018
Share:

Bookmark this article

A lymphoma working party session took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 20 March 2018. Abstract WP7-6 won the Jian-jian Luan award for the best abstract in the topic of Lymphoma. The abstract presented by Anne-Claire Mamez, Hôpitaux Universitaires de Genève, Department of Hematology, Geneva on the role of allogeneic stem cell transplant (allo-SCT) use in patients with peripheral T-cell lymphoma (PTCL).

The retrospective analysis assessed PTCL patients who had allo-SCT between 2006 and 2014 using the Francophone Society of bone marrow transplantation and cellular therapy (SFGM)-TC database. Two-hundred and eighty-four patients were included in the study with a median age of 50 years (range, 16–69) were transplanted at a median of 12.6 months after diagnosis.

Patients received transplant as either first-line treatment (29%), after 2 lines (36%) and after ≥3 lines (35%). The speaker noted that 94% of patients had a Karnofsky performance status of above 80%. The donors for allo-SCT were either matched-related (45%), matched-unrelated (36%) or alternative (19%). Conditioning regimens given included: reduced intensity conditioning (RIC) n = 147, myeloablative (MAC) n = 106 and non-myeloablative (NMA) n = 27.

Key Findings

  • Median follow-up = 33 months
  • 1-year overall survival (OS) = 68% (95% CI, 0.62–0.7) and event-free survival (EFS) = 63% (95% CI, 0.57–0.69)
  • 2-year OS = 64% (95% CI, 0.58–0.7) and EFS = 59% (95% CI, 0.53–0.65)
  • 4-year OS = 57% (95% CI, 0.5–0.63)
  • In a subgroup analysis of 30 patients with progressive disease, 50% achieved a complete response with a 2-year OS of 51%
  • Median time to relapse = 94 days
  • Non-relapse mortality = 22% (1-year) and 24% (2-year)
    • Deaths occurred due to relapse (35%), infection (27%) and graft-versus-host-disease (GvHD; 22%)
  • Grade II-IV GvHD was observed in 31% of patients
  • Chronic GvHD occurred in 34%

The speaker concluded that according to the study findings at long term follow-up, grade ≥3 GvHD and low Karnofsky scores negatively impacted OS. Additionally, the conditioning regimen did not significantly influence OS.

  1. Mamez AC. Et al. Allogeneic stem cell transplantation for peripheral T-cell lymphomas: A study of 284 patients from the société francophone de greffe de moelle et de thérapie cellulaire. Oral abstract WP7-6. EBMT 44th Annual Meeting, Lisbon, Portugal

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox